Orbimed Downgrades its Position in Intercept Pharmaceuticals

Orbimed Advisors, Intercept Pharmaceuticals: In a recent SEC filing, Samuel Isaly and his hedge fund, Orbimed Advisors, reported decreasing their holding in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to 9.22% of its outstanding shares. Orbimed now owns around 1.78 million shares of Intercept, with an aggregate value of $106.34 million, at the current stock price of the company. In its latest 13F, Orbimed reported 2.15 million shares of the company.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Disclosure: none

Recommended Reading:

Wexford Makes Two Thursday Afternoon Moves: Revett & Arno Therapeutics

Steven Cohen May Sell Stock in Company Whose Founder Went to Prison For Insider Trading

Gabelli Also Selling Some Strattec Security Shares